D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 98 Citations 32,784 467 World Ranking 4204 National Ranking 2373

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Gene

Ola Landgren mainly focuses on Internal medicine, Multiple myeloma, Immunology, Monoclonal gammopathy of undetermined significance and Oncology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. His Multiple myeloma research is multidisciplinary, incorporating elements of Incidence, Disease, Pathology, Hazard ratio and Transplantation.

His studies in Immunology integrate themes in fields like Odds ratio, First-degree relatives and Case-control study. Ola Landgren interconnects Genetic predisposition, Immunofixation, Asymptomatic, Prospective cohort study and Veterans Affairs in the investigation of issues within Monoclonal gammopathy of undetermined significance. He works mostly in the field of Oncology, limiting it down to topics relating to Hematology and, in certain cases, Risk profile, Monoclonal gammopathy, Treatment strategy, Dyscrasia and Unknown Significance, as a part of the same area of interest.

His most cited work include:

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. (1706 citations)
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
  • Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study (681 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Internal medicine, Multiple myeloma, Oncology, Immunology and Monoclonal gammopathy of undetermined significance. His Internal medicine research incorporates elements of Gastroenterology and Surgery. His studies deal with areas such as Pathology, Disease, Bone marrow and Minimal residual disease as well as Multiple myeloma.

His Oncology research integrates issues from Clinical trial, Transplantation, Melphalan, Daratumumab and Leukemia. Ola Landgren has researched Immunology in several fields, including Odds ratio and Case-control study. His study looks at the relationship between Monoclonal gammopathy of undetermined significance and topics such as Hazard ratio, which overlap with Proportional hazards model.

He most often published in these fields:

  • Internal medicine (68.40%)
  • Multiple myeloma (59.77%)
  • Oncology (34.04%)

What were the highlights of his more recent work (between 2017-2021)?

  • Multiple myeloma (59.77%)
  • Internal medicine (68.40%)
  • Oncology (34.04%)

In recent papers he was focusing on the following fields of study:

His scientific interests lie mostly in Multiple myeloma, Internal medicine, Oncology, Lenalidomide and Monoclonal gammopathy of undetermined significance. The concepts of his Multiple myeloma study are interwoven with issues in Cancer research, Computational biology and Bone marrow, Minimal residual disease. Ola Landgren conducts interdisciplinary study in the fields of Internal medicine and In patient through his works.

His Oncology study combines topics from a wide range of disciplines, such as Odds ratio, Melphalan, Newly diagnosed, Refractory Multiple Myeloma and Surrogate endpoint. His research integrates issues of Maintenance therapy and Cohort in his study of Lenalidomide. His Monoclonal gammopathy of undetermined significance research includes elements of Peripheral neuropathy, Cancer, Prospective cohort study and Risk factor.

Between 2017 and 2021, his most popular works were:

  • Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma (75 citations)
  • Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS) (73 citations)
  • Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. (62 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Gene

His main research concerns Multiple myeloma, Internal medicine, Oncology, Minimal residual disease and Lenalidomide. His research in Multiple myeloma intersects with topics in Monoclonal gammopathy of undetermined significance, Cancer, Disease and Bone marrow. All of his Internal medicine and Phases of clinical research, Clinical trial, Daratumumab, Cohort study and Odds ratio investigations are sub-components of the entire Internal medicine study.

His Progression-free survival study, which is part of a larger body of work in Oncology, is frequently linked to Risk assessment, bridging the gap between disciplines. His biological study spans a wide range of topics, including Plasma Cell Myeloma, Clone, Drug approval and Somatic evolution in cancer. His Lenalidomide research incorporates elements of Clinical endpoint, Tolerability and Propensity score matching.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)

2775 Citations

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)

1131 Citations

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study

Ola Landgren;Robert A. Kyle;Ruth M. Pfeiffer;Jerry A. Katzmann.
Blood (2009)

1023 Citations

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

R A Kyle;B G M Durie;S V Rajkumar;O Landgren.
Leukemia (2010)

749 Citations

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca.
Blood (2015)

504 Citations

Solid cancers after allogeneic hematopoietic cell transplantation

J. Douglas Rizzo;Rochelle E. Curtis;Gérard Socié;Kathleen A. Sobocinski.
Blood (2009)

472 Citations

B-cell clones as early markers for chronic lymphocytic leukemia.

Ola Landgren;Maher Albitar;Wanlong Ma;Fatima Abbasi.
The New England Journal of Medicine (2009)

433 Citations

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation

Ola Landgren;Ethel S. Gilbert;J. Douglas Rizzo;Gérard Socié.
Blood (2009)

433 Citations

Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

Thomas P. Giordano;Louise Henderson;Louise Henderson;Ola Landgren;Elizabeth Y. Chiao;Elizabeth Y. Chiao.
JAMA (2007)

369 Citations

Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States

Ola Landgren;Gloria Gridley;Ingemar Turesson;Neil E. Caporaso.
Blood (2005)

354 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ola Landgren

Shaji Kumar

Shaji Kumar

Mayo Clinic

Publications: 203

Meletios A. Dimopoulos

Meletios A. Dimopoulos

National and Kapodistrian University of Athens

Publications: 171

S. Vincent Rajkumar

S. Vincent Rajkumar

Mayo Clinic

Publications: 157

Kari Hemminki

Kari Hemminki

Charles University

Publications: 134

Robert A. Kyle

Robert A. Kyle

Mayo Clinic

Publications: 126

Angela Dispenzieri

Angela Dispenzieri

Mayo Clinic

Publications: 125

Morie A. Gertz

Morie A. Gertz

Mayo Clinic

Publications: 122

Evangelos Terpos

Evangelos Terpos

National and Kapodistrian University of Athens

Publications: 120

Philippe Moreau

Philippe Moreau

University of Nantes

Publications: 113

Hartmut Goldschmidt

Hartmut Goldschmidt

University Hospital Heidelberg

Publications: 104

Michele Cavo

Michele Cavo

University of Bologna

Publications: 97

Paul G. Richardson

Paul G. Richardson

Harvard University

Publications: 96

Jan Sundquist

Jan Sundquist

Lund University

Publications: 94

Kenneth C. Anderson

Kenneth C. Anderson

Harvard University

Publications: 91

Gareth J. Morgan

Gareth J. Morgan

New York University

Publications: 91

Nelson Leung

Nelson Leung

Mayo Clinic

Publications: 90

Trending Scientists

Michael Wetter

Michael Wetter

Lawrence Berkeley National Laboratory

Ming-Chun Lu

Ming-Chun Lu

Chia Nan University of Pharmacy and Science

Tadashi Ema

Tadashi Ema

Okayama University

Adam Frankish

Adam Frankish

European Bioinformatics Institute

Bruno Hagenbuch

Bruno Hagenbuch

University of Kansas

Salvatore Auricchio

Salvatore Auricchio

University of Naples Federico II

Roxane Maranger

Roxane Maranger

University of Montreal

Dmitry Schepaschenko

Dmitry Schepaschenko

International Institute for Applied Systems Analysis

Binyamin Hochner

Binyamin Hochner

Hebrew University of Jerusalem

Michael Orth

Michael Orth

University of Ulm

Jørgen A. L. Kurtzhals

Jørgen A. L. Kurtzhals

University of Copenhagen

Renato C. Monteiro

Renato C. Monteiro

Université Paris Cité

David H. Uttal

David H. Uttal

Northwestern University

Pamela J. Goodwin

Pamela J. Goodwin

Lunenfeld-Tanenbaum Research Institute

Carl J. Lavie

Carl J. Lavie

University of Queensland

Jeannette R. Ickovics

Jeannette R. Ickovics

Yale University

Something went wrong. Please try again later.